NCT04934228RecruitingPhase 1
Mitigating the Pro-inflammatory Phenotype of Obesity
Source: ClinicalTrials.gov · Last updated 5 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6). Our study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 31 Mar 2021
- Start date
- 1 Jul 2021
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Obesity
- NCT number
- NCT04934228
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 60
- From 1 Jul 2021 to the primary completion date, 1 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently taking hypertension medication
Other illness
- Current smoker or History of smoking in the past 3 months.
- History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
- History of neurological disorders
- History of transplant
Lab values
- Hyperlipidemia: Fasting triglycerides \> 250 mg/dL
Other
- Current use of clonidine or beta-blockers
- Actively participating in other studies, except for a registry study.
Who the study is looking for
- Male or Female, age 18-79
- Obese: BMI \> 30 m/kg2
- Hypertensive: blood pressure \>130/80
- Elevated insulin resistance (HOMA-IR \> 2.5)
- Waist circ: \>102 cm (men) and \>88 cm (women)
- Fasting glucose \< 126 mg/dL
- Fasting triglycerides \< 250 mg/dL
- HbA1c \< 6.5%
- Willing to visit research lab (Fairway CTSU)
- Willing to undergo a blood draw
- Able to provide written informed consent
Age in the registry: 18 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kansas Medical Center Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.